The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The role of chemoimmunotherapy in the era of targeted therapies for WM
Francesco Autore, MD, PhD, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, discusses the role of chemoimmunotherapy in the treatment of Waldenström’s macroglobulinemia (WM), given the advent of targeted agents. He mentions that bendamustine-rituximab (BR) achieves deep responses in the front line and maybe a better front-line option than BTK inhibitors (BTKis). This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
